Results of treatment and prognosis in patients with localizations of non-Hodgkin's lymphoma in the central nervous system;Behandelresultaten en prognose bij patienten met centralezenuwstelsellokalisaties van het non-Hodgkin-lymfoom

Nederlands Tijdschrift voor Geneeskunde

Volumn 142, Issue 40, 1998, Pages 2196-2200

  Paulus, J A ^a,b   Bos, G M J ^a,b   Lowenberg B ^a,b   Van Den Bent, M J ^a,b  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b Afd Neuro oncologie ^*

Author keywords

[No Author keywords available]

Indexed keywords

LACTATE DEHYDROGENASE;

ADULT; ARTICLE; BRAIN DISEASE; CANCER GRADING; CANCER STAGING; CANCER SURVIVAL; CENTRAL NERVOUS SYSTEM TUMOR; CLINICAL ARTICLE; CLINICAL FEATURE; CRANIAL NEUROPATHY; FEMALE; HEADACHE; HUMAN; LACTATE DEHYDROGENASE BLOOD LEVEL; MALE; MULTIMODALITY CANCER THERAPY; NERVE ROOT COMPRESSION; NONHODGKIN LYMPHOMA; ADOLESCENT; AGED; DISEASE COURSE; INTRASPINAL DRUG ADMINISTRATION; MIDDLE AGED; PALLIATIVE THERAPY; PROGNOSIS; RETROSPECTIVE STUDY; SURVIVAL RATE; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; CENTRAL NERVOUS SYSTEM NEOPLASMS; COMBINED MODALITY THERAPY; DISEASE PROGRESSION; FEMALE; HUMANS; INJECTIONS, SPINAL; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; PALLIATIVE CARE; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 0032480410     PISSN: 00282162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Bollen ELEM, Brouwer RE, Hamers S, Hermans J, Kluin M, Sankatsing SV, et al. Central nervous system relapse in non-Hodgkin lymphoma. A single-center study of 532 patients. Arch Neurol 1997;54:854-9.
2. MacKintosh FR, Colby TV, Podolsky WJ, Burke JS, Hoppe RT, Rosenfelt FP, et al. Central nervous system involvement in non-Hodgkin's lymphoma: an analysis of 105 cases. Cancer 1982;49:586-95
3. Recht L, Straus DJ, Cirrincione C, Thaler HT, Posner JB. Central nervous system metastases from non-Hodgkin's lymphoma: treatment and prophylaxis. Am J Med 1988;84(3 Pt 1):425-35.
4. Ersboll J, Schultz HB, Thomsen BLR, Keiding N, Nissen NI Meningeal involvement in non-Hodgkin's lymphoma: symptoms, incidence, risk factors and treatment. Scand J Haematol 1985;35.487-96.
5. Liang RHS, Woo EKW, Yu YL, Todd D, Chan TK, Ho FC, et al. Central nervous system involvement in non-Hodgkin's lymphoma. Eur J Clin Oncol 1989;25:703-10.
6. Young RC, Howser DM, Anderson T, Fisher RI, Jaffe E, DeVita jr VT. Central nervous system complications of non-Hodgkin's lymphoma The potential role for prophylactic therapy. Am J Med 1979;66:435-43.
7. Keldsen N, Michalski W, Bentzen SM, Hansen KB, Thorling K. Risk factors for central nervous system involvement in non-Hodgkins-lymphoma - a multivariate analysis. Acta Oncol 1996;35.703-8.
8. Johnson GJ, Oken MM, Anderson JR, O'Connell MJ, Glick JH. Central nervous system relapse in unfavourable-histology non-Hodgkin's lymphoma: is prophylaxis indicated? Lancet 1984,ii:685-7.
9. Bent MJ van den, Vecht ChJ. De vele gedaanten van meningitis carcinomatosa. Ned Tijdschr Geneeskd 1994;138:2225-9.
10. Rosenberg SA, Berard CW, Brown BW, Burké, Dorfman JF, Glatstein E, et al. National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas: summary and description of a working formulation for clinical usage. The Non-Hodgkin's Lymphoma Pathologic Classification Project. Cancer 1982;49:2112-35.
11. Shipp MA, Harrington DP. A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 1993;329:987-94.
12. Bos GMJ, Putten WLJ van, Holt B van der, Bent MJ van den, Verdonck LF, Hagenbeek A. For which patients with aggressive non-Hodgkin's lymphoma is prophylaxis for central nervous system disease mandatory? Dutch HOVON Group. Ann Oncol 1998;9:191-4.
13. Carbone PP, Kaplan HS, Musshoff K, Smithers DW, Tubiana M. Report of the Committee on Hodgkin's Disease Staging Classification. Cancer Res 1971;31:1860-1.
14. Sorensen JB, Klee M, Palshof T, Hansen HH. Performance status assessment in cancer patients. An inter-observer variability study. Br J Cancer 1993;67:773-5.
15. Freilich RJ, Krol G, DeAngelis LM. Neuroimaging and cerebrospinal fluid cytology in the diagnosis of leptomeningeal metastasis. Ann Neurol 1995;38 51-7.
16. Macdonald DR, Cascino TL, Schold Jr SC, Cairncross JG. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 1990;8.1277-80.
17. Haddy TB, Adde MA, Magrath IT. CNS involvement in small noncleaved-cell lymphoma: is CNS disease per se a poor prognostic sign? J Clin Oncol 1991;9:1973-82.
18. Sariban E, Edwards B, Janus C, Magrath I. Central nervous system involvement in American Burkitt's lymphoma. J Clin Oncol 1983; 1:677-81.
19. Bent MJ van den. Neurological complications of systemic lymphoma. In: Vecht ChJ, editor. Handbook of clinical neurology. Vol 69. Neuro-oncology. Part III. Neurological disorders in systemic cancer. Amsterdam: Elsevier, 1997:261-87.
20. Yousem DM, Patrone PM, Grossman RI. Leptomeningeal metastases: MR evaluation. J Comput Assist Tomogr 1990;14:255-61.
21. Kersten MJ, Evers LM, Dellemijn PLI, Berg H van den, Portegies P, Hintzen RQ, et al. Elevation of cerebrospinal fluid soluble CD27 levels in patients with meningeal localization of lymphoid malignancies. Blood 1996;87:1985-9.
22. Besien K van, Forman A, Champlin R. Central nervous system relapse of lymphoid malignancies in adults: the role of high-dose chemotherapy. Ann Oncol 1997;8:515-24.